Abstract:Background and Objectives: The purpose of the present study was to compare the results of colposcopic biopsies in patients with breast cancer and those who tested positive for HPV in cervix uteri cytological screenings, with a control group of HPV-positive individuals without breast cancer. Additionally, through this study, we aimed to investigate the impact of tamoxifen treatment, an anti-oestrogen drug used following breast cancer treatment, on histopathological changes. Breast cancer is the most common type of cancer and cause of death in women worldwide. Cervical cancer ranks as the second most prevalent form of cancer among women globally, with prevalence rates ranking just behind those of breast cancer. Human papillomavirus (HPV) positivity is a requirement for the development of cervical cancer, although it is not the sole factor responsible. Materials and Methods: A comparison was made between the histopathological results of 52 patients diagnosed with breast cancer, who tested positive for HPV in routine cervical cytological screenings and underwent colposcopic biopsy, and 230 cases without any abnormalities. A study was conducted to compare healthy individuals between the ages of 30 and 65 who were diagnosed with breast cancer and those who did not have breast cancer. The participants underwent HPV screening as part of the national cervical cytology screening programme. Results: The average age of those diagnosed with breast cancer was 46.73 ± 7.54; in comparison, the average age of participants in the control group was 47.49 ± 7.95. There was no statistically significant difference in age between the two groups (p: 0.530). A total of 51 cases (98.1%) of breast cancer were found to have actively used the anti-oestrogen drug tamoxifen for a duration ranging from at least 6 months to 5 years. One patient (1.9%) in the breast cancer group did not use tamoxifen. During routine cervical cytological screenings, it was observed that both breast cancer cases and healthy cases tested positive for HPV. The most commonly detected types of HPV in both groups were HPV 16 and 18, with rates of 73.1% noted in the breast cancer group and 92.6% noted in the healthy group, results consistent with the rates found in the general population. HPV 16 was found in 58.7% of participants in the control group and 42.3% of participants in the breast cancer group. There was a statistically significant difference between the two groups (p: 0.032). There was no statistically significant difference observed between the two groups in terms of normal, high-grade cervical intraepithelial lesions (HGSILs); low-grade cervical intraepithelial lesions (LGSILs); and chronic cervicitis histopathological lesions based on colposcopic and endocervical biopsy results, smear cytology, and HPV results (p-values of 0.913 and 0.877, respectively). Conclusions: Our study results indicate that tamoxifen treatment, an anti-oestrogen drug administered for chemoprevention purposes in the management of breast cancer, does not lead to an increase in abnormal histological changes in the cervix uteri. In all cases of breast cancer, gynaecological examination and cervical cytological screening should be advised.

The Effects of Tamoxifen on Cervix of the Breast Cancer Patients

The clinic-pathology of gynecological complications in 134 cases of breast cancer

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri

p21~(ras) Expression in Endometrium of Postmenopausal Breast Cancer Patients Treated with Tamoxifen.

Expressions of Ki67,estrogen receptor,and progestogen receptor in endometrium of patients with breast cancer after oral administration of Tamoxifen and the changes of sex hormones levels

Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six‐arm placebo‐controlled trial in healthy women

Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer

Pathological Analysis of 42 Patients with Tamoxifen Associated Endometrial Cancer

Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen

Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients

Association of CYP2D6*10 (c.100c>t) Polymorphisms with Clinical Outcome of Breast Cancer after Tamoxifen Adjuvant Endocrine Therapy in Chinese Population.

Transcervical resection of endometrium for inhibition of proliferative response of endometrium in women with breast cancer on adjuvant tamoxifen

Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer

Postmarketing adverse events of tamoxifen in male and female patients with breast cancer

Protective and Sensitive Effects of Melatonin Combined with Adriamycin on ER+ (estrogen Receptor) Breast Cancer.

Effects of anadrazole and tamoxifen on efficacy and tumor-associated inflammatory factors in hormone receptor-positive patients with metastatic breast cancer after menopause

The effect of estrogen and tamoxifen on the growth of endometrial carcinoma cell

Abstract PO2-12-11: Ocular Toxicity of Tamoxifen in Patients with Breast Cancer

Combined Effects of Goserelin and Tamoxifen on Estradiol Level, Breast Density, and Endometrial Thickness in Premenopausal and Perimenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer: a Randomised Controlled Clinical Trial.